Acadia Pharmaceuticals: Back In The Buy Zone
Summary: Acadia Pharmaceuticals, Inc. shares recently hit their lowest level since Daybue approval due to
Summary: Acadia Pharmaceuticals, Inc. shares recently hit their lowest level since Daybue approval due to
Summary: ACADIA Pharmaceuticals is a biopharmaceutical company specializing in CNS disorder treatments, with two successful
Summary: Acadia’s new drug, Daybue, shows promising initial sales, but pimavanserin failed in schizophrenia trials,
Summary: Acadia Pharmaceuticals stock price dropped over 15% after its drug candidate, pimavanserin, failed to
Summary: Acadia’s DAYBUE drug to treat Rett Syndrome has disappointed recently. DAYBUE patients suffer from
Summary: ACADIA Pharmaceuticals and Soleno Therapeutics are both conducting late-stage trials for the treatment of
Summary: Shares of Acadia Pharmaceuticals surged after the Court granted a summary judgment in the
Summary: Acadia’s Daybue, treating Rett syndrome, shows strong market entry with sales of $90.1 million
Summary: Acadia Pharmaceuticals’ gains recently disappeared despite the strong launch of Daybue. Poor market conditions
Summary: Acadia Pharmaceuticals shows fiscal resilience with a shift to net positive income, buoyed by